Matching articles for "endometrial cancer"
Issue 1748 · February 16, 2026 Free
In Brief: Label Changes for Menopausal Hormone Therapy Products

The FDA has requested the removal of some boxed warnings from the labels of vaginal and systemic menopausal hormone therapy (MHT) products. The warnings were initially added in 2003 based on the results of two…

Med Lett Drugs Ther. 2026 Feb 16; 68(1748):30-1 doi:10.58347/tml.2026.1748d
The FDA has requested the removal of some boxed warnings from the labels of vaginal and systemic menopausal hormone therapy (MHT) products. The warnings were initially added in 2003 based on the results of two placebo-controlled Women's Health Initiative (WHI) trials evaluating the use of systemic hormones for primary prevention of coronary heart disease (CHD) in postmenopausal women 50-79 years old.
Issue 1683 · August 21, 2023 Free
In Brief: A New Endometrial Cancer Indication for Dostarlimab (Jemperli) (online only)

The immune checkpoint inhibitor dostarlimab-gxly ( Jemperli – GSK) has been approved by the FDA for use in combination with carboplatin and paclitaxel for treatment of adults with mismatch repair deficient…

Med Lett Drugs Ther. 2023 Aug 21; 65(1683):e138 doi:10.58347/tml.2023.1683f
The immune checkpoint inhibitor dostarlimab-gxly ( Jemperli – GSK) has been approved by the FDA for use in combination with carboplatin and paclitaxel for treatment of adults with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. Dostarlimab was recently granted regular approval for treatment of adults with dMMR recurrent or advanced endometrial cancer that progressed on or following a prior platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation.
Issue 1673 · April 3, 2023
Dostarlimab (Jemperli) for Endometrial Cancer (online only)

The FDA has granted regular approval to dostarlimabgxly ( Jemperli – GSK), an immune checkpoint inhibitor, for treatment of adults with mismatch repair deficient (dMMR) recurrent or advanced endometrial…

Med Lett Drugs Ther. 2023 Apr 3; 65(1673):e64-5 doi:10.58347/tml.2023.1673h
The FDA has granted regular approval to dostarlimabgxly ( Jemperli – GSK), an immune checkpoint inhibitor, for treatment of adults with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following a prior platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation. Dostarlimab received accelerated approval in 2021 for treatment of adults with dMMR recurrent or advanced endometrial cancer or nonendometrial solid tumors that progressed on or following prior treatment and who have no satisfactory alternative treatment options. About 25-30% of patients with endometrial cancer have dMMR tumors.
Issue 7 · March 1, 2003
Drugs of Choice for Cancer

The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants.…

Treat Guidel Med Lett. 2003 Mar; 1(7):41-52
The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. In some cases, such as elderly patients or those with many co-morbid illnesses, the regimen of choice might not be suitable. For many of the cancers listed, surgery and/or radiation therapy may be the treatment of choice or may also be part of the management. Anticancer drugs and their adverse effects are listed in Table II on page 46. A partial list of brand names appears on page 52.